Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta‐analysis and systematic review
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023
DOI: 10.1002/phar.2859 ↗At a glance
Systematische Übersicht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Written by Jiale Chen and 3 co-authors. Institution: Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China. Major MEDLINE topics: Extracorporeal Membrane Oxygenation, Anticoagulants, Thrombosis. Cited 21 times so far (Crossref); 49 references. Funded by: Jinhua Central Hospital Youth Research Foundation.
Abstract (original language)
Objectives
Extracorporeal membrane oxygenation (ECMO) plays an important role in providing temporary life support for patients with severe cardiac or pulmonary failure, but requires strict anticoagulation and monitoring. This network meta‐analysis systematically explored the most effective anticoagulation and monitoring strategies for patients receiving ECMO.
Methods
MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched up to January 31, 2023, for studies comparing unfractionated heparin (UFH), argatroban (Arg), bivalirudin (Biv), and/or nafamostat mesylate (NM) in patients receiving ECMO. The primary outcomes included device‐related thrombosis, patient‐related thrombosis, and major bleeding events. The secondary outcomes included ECMO survival, ECMO duration, and in‐hospital mortality.
Results
A total of 2522 patients from 23 trials were included in the study. Biv was associated with a decreased risk of device‐related thrombosis (odd ratio [OR] 0.51, 95% confidence interval [CI]: 0.33–0.84) compared with UFH, whereas NM (OR 2.2, 95% CI: 0.24–65.0) and Arg (OR 0.92, 95% CI: 0.43–2.0) did not reduce the risk of device‐related thrombosis compared with UFH. Biv was superior to Arg in decreasing the risk of device‐related thrombosis (OR 0.14, 95% CI: 0.03–0.51). Biv reduced the risk of patient‐related thrombosis compared with UFH (OR 0.44, 95% CI: 0.18–0.85); NM (OR 0.65, 95% CI: 0.14–3.3) and Arg (OR 3.1, 95% CI: 0.94–12.0) did not decrease risk of patient‐related thrombosis compared with UFH. No significant difference was observed in the risk of major bleeding between three alternatives and UFH: Biv (OR 0.54, 95% CI: 0.23–1.3), Arg (OR 1.3, 95% CI: 0.34–5.8), and NM (OR 0.60, 95% CI: 0.13–2.6). NM showed a reduced risk of in‐hospital mortality compared with UFH (OR 0.27, 95% CI: 0.091–0.77), whereas Arg (OR 0.43, 95% CI: 0.15–1.2) and Biv (OR 0.75, 95% CI: 0.52–1.1) did not decrease risk of in‐hospital mortality.
Conclusions
Compared with UFH and Arg, Biv reduces the risk of thrombosis and appears to be a better choice for patients requiring ECMO. NM was associated with a reduced risk of in‐hospital mortality.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
- Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
ORCID profiles: Jiale Chen, Guoquan Chen, Wenyi Zhao, Wenxing Peng
Funding
- Jinhua Central Hospital Youth Research Foundation
Cite
APA
Chen, J., Chen, G., Zhao, W., & Peng, W. (2023). Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta‐analysis and systematic review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2859
Vancouver
Chen J, Chen G, Zhao W, Peng W. Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta‐analysis and systematic review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2859
BibTeX
@article{Chen2023,
author = {Chen, Jiale and Chen, Guoquan and Zhao, Wenyi and Peng, Wenxing},
title = {Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta‐analysis and systematic review},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
doi = {10.1002/phar.2859}
}
EUVIMED